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The kinetics of glucocerebrosidase synthesis and degradation in rat peritoneal macrophages and in human 
fibroblasts have been studied using conduritol B epoxide (CBE), an irreversible and specific inhibitor of 
mammalian glucocerebrosidase. In cultured fibroblasts, higher concentrations of CBE and/or longer times were 
required for inhibition of glucocerebrosidase than were necessary for inhibition of the macrophage enzyme. 
However, inhibition of activity in cell extracts from both cell types showed identical time and concentration 
dependence. After the removal of CBE from cultures, enzyme activity returned to normal with a half-time of 48 h 
for macrophages and 40 h for fibroblasts. The reappearance of enzyme activity was prevented by an inhibitor of 
protein synthesis. Both the rate of synthesis and degradation of glucocerebrosidase enzyme protein were indepen- 
dent of the presence of CBE. The calculated rate of degradation of glucocerebrosidase was confirmed using 
metabolically labelled enzyme in cell cultures. The rate of synthesis for macrophages is 1.8 ng enzyme h - '  mg 
cell protein-' and the rate of degradation is 1.4% h - '  (0.014 h-').  These values were 2.0 ng h - l  mg-' and 0.018 
h- '  for fibroblasts. 
Glucocerebrosidase (glucosylceramide glucohydrolase) is 
a membrane-bound lysosomal hydrolase, which catalyzes the 
hydrolysis of glucocerebroside, a constituent of biological 
membranes. The enzyme has been purified to homogeneity [I, 
21, extensively characterized [3-91 and its gene isolated [lo- 
151. The activity of the enzyme is markedly decreased in the 
tissues of patients with Gaucher disease, a recessive inherited 
disorder characterized by the accumulation of gluco- 
cerebroside in the cells of the reticuloendothelial system [16]. 
Several mutations in the gene for glucocerebrosidase result in 
different clinical subtypes of the disease [17, 181. Correlations 
between phenotypes of Gaucher disease, clinical severity and 
residual enzyme activity in tissues and cells have so far been 
inadequate [I91 (for reviews see [20, 211). However, there are 
some suggestions that there is less activity and less enzyme 
cross-reactive material in some of the phenotypes of Gaucher 
disease [22, 231. The rate of synthesis or degradation of the 
enzyme may be altered for the mutant proteins and, as such, 
may be a clue to understanding the widely different pheno- 
types of Gaucher disease. The present report describes the 
kinetics of glucocerebrosidase synthesis and degradation in 
cultured human fibroblasts from normal subjects and rat 
peritoneal macrophages using conduritol B epoxide, a specific 
and irreversible inhibitor of glucocerebrosidase [24, 251. 
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sulkte. 
Enzyme. Glucosylceramide glucohydrolase (EC 3.2.1.45). 
MATERIALS AND METHODS 
Muterials 
Conduritol B epoxide (CBE) was prepared according to 
Legler [26]. ~-[1-~~C]Glucosylceramide (0.34 Ci/mol) was syn- 
thesized according to Brady et al. [27]. The Collowing com- 
pounds and materials were purchased from the indicated 
sources: MEM a medium from Grand Island Biological Co. 
(N.Y.); McCoy's 5A and Dulbecco's minimum essential medi- 
um from M. A. Bioproducts (Walkersville, MD); [35S]- 
methionine (1 185 Ci/mmol) from ICN Pharmaceuticals Inc. ; 
thioglycollate from BBL (Cockeysville, MD); iodoacetamide 
from Aldrich Chemical Co. ; triethanolamine from Fisher 
Scientific Co. and Protein-A - Sepharose from Pharmacia 
Fine Chemicals (Uppsala, Sweden). 
Cell cultures 
Media composilioti. a-Mops: MEM a medium (Gibco 
430-1900) was supplemented with 0.4 g/l NaC1, 4.01 g/l 
3-N-[morpholino]propanesulfonic acid (Mops), and 2.25 mljl 
NaOH (5 M), final pH 7.2. a-10: MEM CI medium was supple- 
mented with 2.2 g/1 NaHC03, 10% fetal calf serum, pH 7.2. 
Both media contained 100 U penicillin and 100 pg 
streptomycin/ml. 
Macrophages were collected by peritoneal lavage from 
rats (Sprague-Dawley, 150 - 200 g) given intraperitoneal in- 
jections of 10 ml 10% thioglycollate broth 5 days before 
harvest as described earlier [28]. After killing by COz inhala- 
tion, exudate cells were harvested from the peritoneal cavity 
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Fig. 1. In vivo inhibition of mucrophuge andfibroblast glucocerebrosidase by CBE. Macrophage and fibroblast monolayers were incubatcd at 
37°C for 2 h with various concentrations of CBE. Cells were then harvested and washed with NaCI/Pi, extracts were made and 
glucocerebrosidase was assayed in the cell extract. Enzyme activity was normalized to cell protein and inhibition was calculated as percentage 
of control untreated cells. (A) Macrophages, 1.75 pM CBE for 50% inhibition. (B) Fibroblasts, 36 pM for 50% inhibition. Inserts: kinetics 
of inhibition a t  10 pM CBE. Cells were preincubated with 10 pM CBE for indicated period and then assayed for activity as described above. 
(A) Macrophages, t l12 of inactivation = 30 min. (B) Fibroblasts, t l i z  of inactivation = 4 h 
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Fig. 2. In vitro inhibition oftnucrophuge (0-0) und,fibroblast (n-n) glucocerebrosiduse by CBE. Cell extracts wcre assayed for 
glucocerebrosidase in the presence of indicated concentration of CBE. (A) Dose effect of CBE without preincubation. (B) Kinetics of inhibition 
by CBE. Cell extracts were preincubated with 50 pM CBE for indicated period and then assayed for activity 
in a-Mops medium and plated into tissue-culture dishes with 
a 3s-mm-diameter well (no. 3506 Costar, Cambridge, MA). 
After incubation for 2 h at 37"C, non-adherent cells were 
removed by thorough washing. The remaining adherent 
macrophages were cultivated for 24 h at 37°C in a-10 medium 
in an incubator (5% C02/air) before further studies. Cultures 
prepared in this manner contained more than 95% macro- 
phages, as judged by their ability to take up latex beads and 
by morphology. 
Normal human foreskin fibroblasts were obtained from 
Meloy Laboratories (Springfield, VA). Cells were grown in 
McCoy's SA medium containing 10% fetal calf serum, 
gentamycin (100 pg/ml) and fungizone (2.5 pg/ml), at 37°C in 
an atmosphere of 95% air/S% COz. 
Inhibirion studies with CBE 
CBE, freshly prepared as a stock solution of 1 mM in 
either CI medium containing 10% fetal calf serum or McCoy's 
medium containing 10% fetal calf serum was added to macro- 
phage or fibroblast cell cultures at the concentrations in- 
dicated. After incubating the cells for various time periods the 
medium was aspirated and monolayers were rinsed three times 
with phosphate-buffered saline (NaCl/Pi). Cells were then 
harvested with a rubber policeman and washed with NaC1/ 
Pi. Cell extracts were made by suspending the pellet in buffer 
(0.1 M citrate/phosphate buffer, pH 6.0 containing 0.2% 
TritonX-loo), sonicating briefly (10 s) in a cell disrupter (Heat 
Systems, Ultrasonics Inc.) and then centrifuging at 48000 x g 
for 20 min. Glucocerebrosidase was assayed in the super- 
natant with [1-'4C]glucosylceramide according to the method 
described [2]. 
Imrnunaprecipitation studies 
Cellular glucocerebrosidase was immunoprecipitated with 
polyclonal rabbit anti-glucocerebrosidase antibodies raised 
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Fig. 3 .  Time course of reappearance ofglucocerebrosidase in CBE-treated cells after removal of CBE. Macrophage and fibroblast monolayers 
were treated with 100 pM CBE for 16 h, washed three times with medium and cultured further without CBE. Cells were harvested at different 
time intervals, washed with NaCl/Pi and extracts were made and assayed for glucocerebrosidase activity. Enzyme activities were normalized 
to cell protein. (0-0) Cells treated with CBE, (A-A) control cells without CBE treatment. (A) Macrophages, (B) fibroblasts 
I 
4 8 12 16 20 24 
TIME IN H 
Fig. 4. Treatment of cells with cycloheximide after removal of CBB. 
Macrophage monolayers were first treated with 100 pM CBE for 
16 h. Cells were then washed free of CBE, treated with cycloheximide 
(0.2 mM) for various time periods (2-8 h), washed free of 
cycloheximide and cultured further up to 24 h. Glucocerebrosidase 
was assayed in the cell extracts made from cells harvested at various 
time points after removal of cycloheximide. Cells were treated with 
cycloheximide for (0-0) 0 h, (A-A) 2 h, (0--0) 4 h,  
(0-0) 6 h and (A-A) 8 h 
against purified homogeneous human placental enzyme [2]. 
Since the antibody does not cross-react with rat gluco- 
cerebrosidase (unpublished data), all the immunopre- 
cipitations and studies of the rate of synthesis were done in 
human fibroblasts. Cells, first starved for 2 h in methionine- 
free Dulbecco's minimal essential medium containing 10% 
dialysed fetal calf serum were pulsed for 1 h with [j5S]- 
methionine (262 pCi/ml) in the same medium. Cells were 
washed twice with NaC1/Pi and the medium was replaced with 
medium containing methionine. After various lengths of time, 
cells were harvested, washed with NaCI/P, and suspended in 
Tris/HCI, pH 7.0. Cells from one T-25 flask were suspended in 
200 p1 Tris/HCl (50 mM, pH 7.0) containing 20 mM sodium 
phosphate and 2.5 mM dithiothreitol and kept frozen. After 
thawing, 5.25 pl sodium dodecyl sulfate (SDS) (20%) and 
aprotinin (100 U) were added and the suspension was boiled 
for 2 min, cooled and sonicated for 30 s. After centrifugation 
at 50000 x g for 20 min, the supernatant was carefully re- 
moved using a thinly drawn-out pasteur pipette. To the 
supernatant, 65 pl diluting buffer (100 mM Tris, pH 7.4 
containing 20% Triton X-100, 300 mM NaC1,lO mM EDTA 
and 400 U/ml aprotinin), 6.5 pl iodoacetamide (0.5 M) and 
5 pl rabbit anti-glucocerebrosidase serum were added and 
incubated for 1 h at  37"C, then overnight at 4°C. The 
suspension was then centrifuged at 50000 x g for 10 min and 
the supernatant was again carefully removed. 25 pI protein- 
A - Sepharose beads were added as a 1 : 1 slurry in NaCI/P, 
and the resulting suspensions was incubated at room tempera- 
ture for 3 h. After centrifugation at 12000 x g  for 2 min, 
supernatant was carefully removed and the beads were washed 
four times with washing buffer (150 mM triethanolamine, pH 
7.4, containing 150 mM NaC1, 0.1% SDS and 5 mM EDTA). 
Beads were solubilized with 1 YO SDS in NaCl/Pi and counted. 
RESULTS 
Inhibition of macrophage and fibroblast glucocerebrosidase 
by CBE 
Inhibition of glucocerebrosidase by CBE in cultured 
macrophages or fibroblasts was shown to be both time and 
concentration dependent. However, the rate and extent of 
inhibition were different for these two cell types. In a 2-h 
incubation the concentration required for 50% inhibition of 
the macrophagge enzyme activity was 1.75 pM CBE 
compared with 36 pM for fibroblasts (Fig. 1). At 10 pM CBE, 
the t l j z  (the time required to inhibit 50% of initial activity) 
was about 30 min for macrophages and 4 h for fibroblasts 
(inserts, Fig. 1). Complete inhibition was achieved when both 
cells were treated with 100 pM CBE for 16 h. When cell ex- 
tracts from both cells were treated with CBE (Fig. 2), the rate 
and extent of inhibition were found to be similar (k 10Yo) 
suggesting a differential in vivo effect of CBE on macrophages 
and fibroblasts. This may be due to poorer permeability or 
transport of CBE in fibroblasts compared to macrophages. 
Reappearance of glucocerebrosidusc activity 
after CBE treatment 
The in vivo inhibitory effect of CBE on macrophage and 
fibroblast glucocerebrosidase was found to be reversible. 
After completely inhibiting glucocerebrosidase activity by 
treatment with 100 pM CBE for 16 h and then washing cells 
free of CBE, the enzyme activity returns slowly as shown in 
Fig. 3 and reached normal levels approximately 5 days after 
removal of CBE. Enzyme activity was half normal at 48 h for 
macrophages and 40 h for fibroblasts. 
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Fig. 5. ( A )  Degradation of metabolically labelled glucocrrebrosidase in ,fihrohlasts. ( B )  SDS/polyucrylumi& gel eleciropl~o,c.vis of' 
immunoprecipitated glucocerebrosidase. (A) Cells were pulsed with [3sS]methionine (262 pCi/ml) for 1 h, chased and at indicated times the 
radioactivity incorporated into glucocerebrosidase was determined by immunoprecipitation as described in Matcrials and Methods. Degrada- 
In  prescnce of 10 bM CBE. (B) [35S]Methionine-labelled samples immunoprecipitated as above were clectrophoresed on 10% Lacmmli gels 
and autoradiographed as described in [V]. Lane I ,  0 chase; lane 2, 48-h chase. ['4C]Carboxymethylated protcin standards are included for 
reference 
tion was calculated as a percentage ofglucocerebrosidase radioactivity at 0 time after [3sS]methionine pulse. (0-0) No CBE. ( x ~ x )  
Table 1. Relative rate ofjibroblust glucocerc2brosidase synthesis at infervuls ufter treatment with CBE 
Cells were preincubated with 100 pM CBE for 16 h and then washed free of CBE. At intervals following this washout, cells were pulsed with 
[35S]methionine (262 pCi/ml) and the radioactivity incorporated into fibroblast glucocerebrosidase and total trichloroacetic-acid-precipitable 
protein was determined as described in Materials and Methods. The data represcnt the mean f SD for triplicate determinations 
Time after Fibroblast glucocerebrosidase (a)  Glucocerebrosidase ( b )  Protein a,h X103 
CBE removal activity (mean f SD) radioactivity (mean) radioactivity (mean) (mean SD) 
h units/mg cell protein cpm x 10-~/mgcel l  protein 
No treatment 226 _+ 17 
0 3 +  1 
17 47_+ 6 
24 64+ 7 
46 112+ 9 
70 163 f 13 
94 191 _+ 16 
8.1 
9.2 
8.7 
8.8 
8.5 
8.6 
8.3 
8965 
YO74 
8525 
8244 
8719 
8427 
8372 
0.90 0.03 
1.01 k0.11 
1.02 _+ 0.10 
1.07 f 0.06 
0.97 f 0.06 
1.01 T0.18 
0.99 i 0 . 1 5  
The reappearance of glucocerebrosidase activity was 
shown to represent new synthesis of the enzyme in studies 
with cycloheximide, a reversible inhibitor of protein synthesis. 
Cells treated with 100 pM CBE for 16 h were washed and 
then pulsed with cycloheximide (0.2 mM) for various times 
(Fig. 4). Reappearance of activity was delayed in proportion 
to the duration of cycloheximide treatment indicating that 
new protein synthesis is required for enzyme recovery. 
Rates of .synthesi.y and degradation of nlucocerebrosiduse 
Since CBE is an irreversible inhibitor of glucocere- 
brosidase, the reappearance of activity to a steady-state level 
can be utilized to calculate the rate of synthesis of the protein. 
This presumes, however, that the rates of synthesis and degra- 
dation are not altered by CBE treatment. This assumption 
was checked by comparing, in control and CBE-treated cells 
the amount of [35S]methionine incorporated into gluco- 
cerebrosidase at  various times after CBE preincubation. No 
significant differences were observed in the ratios of gluco- 
cerebrosidase radioactivity to total protein radioactivity be- 
tween control and treated cells (Table 1). 
Similarly the rate of disappearance of the label in 
glucocerebrosidase from control and CBE-treated cells was 
not different (Fig. 5) .  SDS/polyacrylamide gel electrophoresis 
followed by autoradiography shows that all radioactivity 
immunoprecipitated by this method is associated with protein 
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Fig. 6. ( A )  Kinetics of mucrophuge (0-0) und,fibrohlust (/"A) glucocerebrosidase degradation in vivo. ( B j  Comparison qf the 
kinc.tics qf'degrudation of fibroblust glucocerebrosidase cukuluted,from the reuppearance of' enzyme activity after CBE treatment with the kinetics 
qfdisuppearunce ofpulse-labeled enzyme radioactivity. (A) Data from Fig. 3, replotted as log (cN-c,) versus time, in which cN is the normal 
level of glucocerebrosidase in respective cells and c, is the enzyme level at  various times after removal of CBE. Each point represents the 
average of three experiments. k D  is the first-order constant for glucocercbrosidase degradation, as determined by the slope of the linc. k,, the 
rate of glucocerebrosidase synthesis, equals kDcN. (B) (Ap-- ~-A) Semilogarithmic plot of cN -c, versus time as described in (A). (o-~ -0) 
Semilogarithmic plot of glucocerebrosidase radioactivity immunoprecipitatcd after [35S]mcthionine pulse versus time 
bands corresponding in molecular mass to glucocerebrosidase 
[2,171. 
Kinetics of return qf glucocerehrosidase activity 
The method by which the rate of synthesis and degradation 
of glucocerebrosidase was determined is that of Price et al. 
[29]. which is based on certain assumptions. The assumptions 
are (a) that glucocerebrosidase is being synthesized at a 
constant rate, ks and (b) that a constant fraction, (kD), of the 
active glucocerebrosidase molecules is being degraded per unit 
of time. From these assumptions the following equation can 
be derived 
If c = 0 at t = 0, a condition obtained before removal of 
CBE, then 
where c, represents the enzyme level at any time, 1, after 
removal of the inhibitor (CBE). 
At the steady-state level, c N ,  the rate of glucocerebrosidase 
synthesis equals the rate of degradation. Hence, if kD is known, 
ks can readily be calculated from the equation: 
ks = kntN. (3) 
A linear transformation of Eqns (2) and (3) permits 
graphic evaluation of kD 
I o ~ ~ , - , ( c N - c , )  = (-kD log,,e)t + log1,tN. (4) 
In the experiment depicted in Fig. 4 the time course of 
return of glucocerebrosidase to the steady state after CBE 
treatment was compared between macrophages and 
fibroblasts. The difference between the activity at any time 
after CBE removal and the steady-state value (mean), 
obtained from control untreated cclls, was plotted on a 
semilogarithmic scale against time (Fig. 6A). kD was estimated 
from the slope of the line according to Eqn (4) and ks from 
Eqn (3). We have calculated that for macrophages 3.6 units 
o r  I .8 ng glucocerebrosidase mgcell protein-' hK1 were being 
synthesized and 1.4% of the enzyme molecules present were 
being destroyed in that time (k, = 0.014 h-'). For fibroblasts 
these values are 4.0 units or 2.0 ng and 1.8% (0.018 h-') for 
synthesis and degradation respectively. For this calculation 
the specific activity of glucocerebrosidase is assumed to be 
2 x lo6 units/mg (equivalent to that of the purified placental 
enzyme [2]). The rate of degradation in fibroblasts (k ,  
= 0.015 h-'), calculated from the rate of disappearance of 3 5 S  
label in immunoprecipitated enzyme (Fig. 6B), independently 
confirms the rate determined from steady-state calculations, 
thus increasing the confidence in this measurement. 
DISCUSSION 
CBE, a potent irreversible inhibitor of various plant 
glucosidases [30], has been shown to be an effective inhibitor 
of mammalian glucocerebrosidases [24, 251. We have demon- 
strated that CBE inhibits glucocerebrosidase in cultured 
macrophages and fibroblasts to different extents. In contrast, 
glucocerebrosidase in extracts from both these cell types was 
found to be equally sensitive to CBE inhibition. This differ- 
ence most likely is due to poorer permeability or transport of 
CBE in fibroblasts than in macrophages. 
The complete inhibition of macrophage and fibroblast 
glucoccrebrosidase by CBE was found to be followed by a 
progressive return of the enzyme activity to normal levels in 
5 days after removal of CBE from the culture medium. Studies 
in mice have shown that a single injection of CBE produced 
near complete inhibition of glucocerebrosidase in various 
tissues and activity returned to about 80"h of normal within 
16 days [31]. We have used steady-state assumptions to calcu- 
late the rates of synthesis and degradation from the re- 
appearance of enzyme activity after removal of the inhibitor. 
These calculations assume that the return of activity is due to 
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new synthesis of enzyme protein rather than reactivation of 
the enzyme. By use of cycloheximide pulses, the return of 
enzyme activity was delayed, thus demonstrating the require- 
ment for new protein synthesis in this process. These 
calculations also rely on the evidence provided earlier [28] 
that no residual CBE remains after washout to inhibit newly 
synthesized enzyme and thus prevent accurate measurement 
of the rate of synthesis of new enzyme molecules. These experi- 
ments show that macrophages and fibroblasts have similar 
rates of synthesis and degradation of glucocerebrosidase 
implying thereby that the process of turnover of this enzyme 
is not cell-specific. Both the rates of synthesis and degradation 
of the enzyme protein were found to be unaffected by the 
presence of CBE. The ability to independently confirm the 
rate, determined using the approach to steady-state cal- 
culations by specific immunoprecipitation of 35S-labeled 
enzyme, builds confidcncc in the ability to use these methods 
for the measurement of synthesis and degradation in mutant 
cells. The turnover of lysosomal p-galactosidase was studied 
earlier in fibroblasts from patients with different types of 
p-galactosidase deficiency using the suicide substrate P-D-ga- 
lactopyranosylmethyl-p-nitrophenyltriazene [32]. This meth- 
od described here promises to be of considerable value for 
studying the turnover rates in the several different mutations 
of glucocerebrosidase. Similar approaches may contribute to 
understanding the differences in the mutations of the gene(s) 
for other enzymes. 
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